Zobrazeno 41 - 50
of 107
pro vyhledávání: '"Daniel S Chen"'
Publikováno v:
Clinical Cancer Research. 18:6580-6587
The aim of T-cell–based immune therapy for cancer has been to generate durable clinical benefit for patients. Following a generation of therapies that largely showed minimal activity, substantial toxicity, and no biomarkers to identify which patien
Autor:
Jennifer Jones, Daniel T. Chang, Daniel S. Chen, Joseph A. Mollick, Susan M. Hiniker, Susan M. Swetter, Susan J. Knox, Sunil Reddy
Publikováno v:
Translational Oncology. 5(6):404-407
BACKGROUND: Melanoma is a relatively immunogenic tumor, in which infiltration of melanoma cells by T lymphocytes is associated with a better clinical prognosis. We hypothesized that radiation-induced cell death may provide additional stimulation of a
Autor:
Daniel S. Chen, Ira Mellman
Publikováno v:
Nature. 541(7637)
Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But despite the clinical success of antibodies against the immune regulators CTLA4 and PD-L1/PD-1, only a subset of people exhibit durable responses, suggesting
Autor:
Patrick Hwu, Israel Lowy, Michael Kalos, Hy Levitsky, Nils Lonberg, E. John Wherry, Charles G. Drake, Matthew J. Tontonoz, Ira Mellman, Daniel S. Chen, James P. Allison, Sjoerd H. van der Burg, Douglas T. Fearon, Vanessa M. Hubbard-Lucey, Robert H. Vonderheide
Publikováno v:
Cancer Immunology Research, 4(4), 279-288
With the recent FDA approvals of pembrolizumab and nivolumab, and a host of additional immunomodulatory agents entering clinical development each year, the field of cancer immunotherapy is changing rapidly. Strategies that can assist researchers in c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::739d09497e6ab8c2c91a17e56b4994f2
http://hdl.handle.net/1887/111778
http://hdl.handle.net/1887/111778
Autor:
Daniel S. Chen, J.M. Kim
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 27(8)
The emergence of programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1)-targeted therapy has demonstrated the importance of the PD-L1 : PD-1 interaction in inhibiting anticancer T-cell immunity in multiple human cancers, generating durable respo
Autor:
Louis, Fehrenbacher, Alexander, Spira, Marcus, Ballinger, Marcin, Kowanetz, Johan, Vansteenkiste, Julien, Mazieres, Keunchil, Park, David, Smith, Angel, Artal-Cortes, Conrad, Lewanski, Fadi, Braiteh, Daniel, Waterkamp, Pei, He, Wei, Zou, Daniel S, Chen, Jing, Yi, Alan, Sandler, Achim, Rittmeyer, Charles, Weissman
Publikováno v:
Lancet (London, England). 387(10030)
Outcomes are poor for patients with previously treated, advanced or metastatic non-small-cell lung cancer (NSCLC). The anti-programmed death ligand 1 (PD-L1) antibody atezolizumab is clinically active against cancer, including NSCLC, especially cance
Autor:
Fabien Gaire, Neeraj Sharma, Xian He, James W. Mier, Genevive Hernandez, David F. McDermott, Mario Sznol, Konstanty Korski, Jeffrey Wallin, Roel Funke, Galina Babitski, Daniel Waterkamp, Priti S. Hegde, Vincent Leveque, Daniel S. Chen, Hartmut Koeppen, James Ziai, Johanna C. Bendell, Marta Cañamero, Mitchell Denker, F. Stephen Hodi, Suzanne F. Jones
Publikováno v:
Nature Communications
Nature Communications, Vol 7, Iss 1, Pp 1-8 (2016)
Nature Communications, Vol 7, Iss 1, Pp 1-8 (2016)
Anti-tumour immune activation by checkpoint inhibitors leads to durable responses in a variety of cancers, but combination approaches are required to extend this benefit beyond a subset of patients. In preclinical models tumour-derived VEGF limits im
Autor:
Peter Cheverton, David F. McDermott, William E. Carson, Gerald P. Linette, Kevin B. Kim, Jeffrey A. Sosman, Hoa Nguyen, Amy C. Peterson, Daniel S. Chen, Svetomir N. Markovic, John P. Fruehauf, Jeffrey S. Weber, Steven J. O'Day
Publikováno v:
Journal of Clinical Oncology. 30:34-41
Purpose Metastatic melanoma, a highly vascularized tumor with strong expression of vascular endothelial growth factor, has an overall poor prognosis. We conducted a placebo-controlled, double-blind phase II study of carboplatin plus paclitaxel with o
Autor:
Geetha Shankar, Roel Funke, Naiyer A. Rizvi, Daniel Waterkamp, Garret Hampton, David S. Shames, Alan Sandler, Marcin Kowanetz, Lukas C. Amler, Priti S. Hegde, Garrett M. Frampton, Susan Flynn, Marcus Ballinger, Daniel S. Chen, Alexander I. Spira, Matthew D. Hellmann, Simonetta Mocci, Craig Cummings, Vincent Leveque, Wei Zou
Publikováno v:
Journal of Thoracic Oncology. 12:S321-S322
Autor:
Pei He, Keunchil Park, Marcin Kowanetz, Dariusz M. Kowalski, Achim Rittmeyer, Shirish M. Gadgeel, Joachim von Pawel, Fortunato Ciardiello, Joseph W. Leach, Toyoaki Hida, Daniel Waterkamp, Diego Cortinovis, Marcus Ballinger, Jonathan Polikoff, Daniel S. Chen, David R. Gandara, Fabrice Barlesi, Manuel Cobo Dols, C. Matheny, Carlos H. Barrios, Alan Sandler
Publikováno v:
Journal of Thoracic Oncology. 12:S9-S10